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Objective: The long-term effects of aliskiren in hypertensive hemodialysis patients remain 
to be elucidated.
Design: In this post hoc analysis, we followed up 25 hypertensive hemodialysis patients who 
completed 8-week aliskiren treatment in a previous study for 20 months to investigate the blood 
pressure-lowering effect and inhibitory effect on the renin-angiotensin-aldosterone system.
Results: Among the 25 patients, eleven patients continued with aliskiren treatment. Blood 
pressure (± standard deviation) decreased from 175 ± 18/80 ± 11 mmHg at baseline to 
156 ± 20/76 ± 9 mmHg at month 20. Plasma renin activity, angiotensin I, and angiotensin II 
decreased from baseline to month 20 (plasma renin activity (ng/mL/h): 2.3 ± 2.6 to 0.3 ± 0.4 
(P , 0.05), angiotensin I (pg/mL): 909.1 ± 902.5 to 41.5 ± 14.8 (P , 0.05), angiotensin II 
(pg/mL): 41.5 ± 45.8 to 11.0 ± 4.9 (P , 0.05)).
Conclusion: Long-term treatment with aliskiren provides effective blood pressure lowering 
and inhibition of the renin-angiotensin-aldosterone system, which are sustained over 20 months 
in hypertensive hemodialysis patients.
Keywords: aliskiren, blood pressure, renin, angiotensin, aldosterone, hemodialysis patients, 
long-term effects
Introduction
Hypertension and cardiovascular disease (CVD) are common in hemodialysis (HD) 
patients.1–3 Recent meta-analyses demonstrated that antihypertensive pharmacotherapy 
reduced CVD in HD patients.4,5 The renin-angiotensin-aldosterone system (RAAS) 
contributes to hypertension and CVD in hypertensive HD patients.6,7 Previous studies 
suggested that RAAS blockers such as angiotensin I converting enzyme inhibitors 
(ACEIs) and angiotensin receptor blockers (ARBs) were effective for blood pressure 
(BP) control and CVD protection in hypertensive HD patients.8–13
In a previous study, we reported that an oral direct renin inhibitor, aliskiren, was 
effective for BP control and could have CVD protective effects in hypertensive HD 
patients in 8-week treatment periods;14 however, its long-term effects in hyperten-
sive HD patients remain to be elucidated. In this post hoc analysis, we followed up 
the hypertensive HD patients who completed the previous study for 20 months to 
investigate the BP-lowering effect and inhibitory effects on RAAS and surrogate 
markers of CVD, such as brain natriuretic peptide (BNP) and an oxidative stress 
marker, diacron-reactive oxygen metabolites (d-ROM), of aliskiren in hypertensive 
HD patients.
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Methods
This study was performed in accordance with the   Declaration 
of Helsinki and was approved by the ethics committee of Jichi 
Medical University. Written informed consent was obtained 
from all patients.
Patients and study protocol
Details of the protocol of aliskiren for hypertensive HD 
patients in the 8-week trials in the previous study have been 
published previously.14 Briefly, the study was a multicenter 
clinical trial of 30 hypertensive HD patients. Subjects were 
enrolled between January 2010 and February 2010 and 
assigned aliskiren at 150 mg orally in the morning once daily 
with their existing antihypertensives. The end point of the 
previous study was to determine the changes of RAAS, BP, 
and surrogate markers of CVD after 8 weeks of aliskiren 
treatment. After the end of the previous study, the continu-
ation of aliskiren treatment was determined by physicians 
on basis of the patients’ BP levels. As shown in Figure 1, in 
this post hoc analysis, we followed up the hypertensive HD 
patients who completed the previous study for 20 months to 
investigate the changes of BP, RAAS, and surrogate markers 
of CVD in both hypertensive HD patients who continued 
with aliskiren treatment (aliskiren group) and those who were 
withdrawn from aliskiren treatment (aliskiren-withdrawal 
group).
Monitoring BP, RAAS, and CVD surrogate 
markers
Systolic BP (SBP) and diastolic BP (DBP) were measured 
before all HD sessions. The reported monthly SBP and DBP 
were the average of each SBP and DBP on the last HD day of 
the week. Blood samples were obtained from arteriovenous 
shunt before HD sessions. Plasma renin activity (PRA), 
angiotensin I (AT I), angiotensin II (AT II), aldosterone (Ald), 
BNP, and d-ROM levels were compared at baseline and at 
months 2 and 20. Standard laboratory tests were performed 
in the observation period in each month in the treatment 
period.
Laboratory methods
PRA, Ald, and BNP levels were determined by the radioim-
munoassay method. AT I and AT II levels were measured 
by a double antibody radioimmunoassay method; the details 
of these methods have been described elsewhere.15,16 PRA, 
AT I, AT II, BNP, and other blood chemistry levels were 
  determined by a clinical chemistry laboratory (SRL, Inc, 
Tokyo, Japan). d-ROM values were measured using the Free 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
46
Morishita et al
Aliskiren group
n = 14
Completed previous study
n = 25
Aliskiren-withdrawal group
n = 11
Withdraw aliskiren 
at 3–8 months
Enrolled aliskiren treatment
n = 30
2 months
20 months
Analysis
n = 11
Analysis
n = 10
Death n = 2
Transfer n = 1 Death n = 1
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Radical Analysis System 4 (Wismerll, Tokyo, Japan); the 
details of this method have been described elsewhere.17,18
Statistical analysis
All data are expressed as the mean ± standard deviation. 
Baseline characteristics were compared between groups with 
unpaired t-test. The parameters within each group were com-
pared with paired t-test. Differences with a P-value , 0.05 
were considered significant.
Results
In a previous study, 25 of 30 hypertensive HD patients 
completed an 8-week aliskiren treatment trial. Twenty-three 
of the 25 patients had been taking antihypertensive drugs 
before aliskiren treatment, including calcium antagonists 
(16 patients), ACEIs (six patients), ARBs (18 patients), 
β-blockers (four patients), α-blockers (seven patients), 
αβ-blockers (four patients), and α-methyldopa (five 
patients). Among these 25 patients, 11 patients continued 
aliskiren treatment with their pre-existing antihypertensives 
including calcium antagonists (four patients), ARBs (seven 
patients), β-blockers (two patients), and α-blockers (three 
patients) during this study period (aliskiren group). Ten 
patients were withdrawn from aliskiren treatment from 
month 3 to month 8 (month 3, one patient; month 4, three 
patients; month 6, two patients; month 7, two patients; and 
month 8, two patients) owing to symptomatic hypotension. 
These ten patients had their BP controlled by antihyper-
tensives other than aliskiren including calcium antagonists 
(eight patients), ACEIs (three patients), ARBs (eight 
patients), β-blockers (two patients), α-blockers (three 
patients), αβ-blockers (four patients), and α-methyldopa 
(three patients) during this study period (aliskiren-with-
drawal group). Two patients died of heart failure under 
aliskiren treatment (one patient) and after withdrawal 
from aliskiren treatment (one patient) and one patient 
died of pneumonia under aliskiren treatment. One patient 
was transferred to hospital. These four patients were 
excluded from analysis. Table 1 shows the characteristics 
of the study patients in both the aliskiren group and the 
aliskiren-withdrawal group at baseline. There were no 
statistical differences in age, body mass index, time on 
dialysis, average time of a dialysis, average ultrafiltration, 
and duration of hemodialysis between the aliskiren group 
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Table 1 Patients’ baseline characteristics
Parameter Aliskiren group Aliskiren-withdrawal group P value
Number 11 10
Age (years) 66.3 ± 7.4 67.2 ± 8.1 0.56
gender
  Male 7 5
  Female 4 5
BMI (kg/m2) 23.2 ± 3.0 23.8 ± 3.1 0.42
Time on dialysis (weeks) 2.9 ± 0.2 2.8 ± 0.2 0.51
Average time of the dialysis (hours) 4.0 ± 0.2 4.0 ± 0.3 0.63
Average ultrafiltration (kg/hours/HD section) 2.8 ± 1.1 2.7 ± 1.4 0.81
Duration of hemodialysis (years) 6.9 ± 7.2 6.8 ± 6.2 0.76
Initial nephropathy
  Chronic glomerulonephritis 2 2
  Diabetic nephropathy 7 4
  ANCA-associated glomerulonephritis 0 1
  Drug nephropathy 0 1
  Malignant hypertension 1 0
  Unknown 1 2
SBP (mmHg) 175.0 ± 18.0 171.0 ± 13.0 0.30
DBP (mmHg) 80.0 ± 11.0 80.0 ± 14.0 0.89
HR (beats/minute) 78.0 ± 12.0 76.0 ± 10.0 0.91
PRA (ng/mL/hr) 2.3 ± 2.6 3.3 ± 2.9 0.41
ATI (pg/mL) 909.1 ± 902.5 999.1 ± 844.6 0.82
ATII (pg/mL) 41.5 ± 45.8 30.6 ± 36.7 0.56
Ald (pg/mL) 163.5 ± 214.3 97.2 ± 57.5 0.58
BNP (pg/mL) 248.9 ± 197.2 425.3 ± 207.3 0.06
d-ROM (U.CARR) 386.6 ± 123.1 402.3 ± 69.0 0.72
Abbreviations: BMI, body mass index; HD, hemodialysis; ANCA, SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; PRA, plasma renin activity; 
ATI, angiotensin I; ATII, angiotensin II; Ald, aldosterone; BNP, brain natriuretic peptide; d-ROM, diacron-reactive oxygen metabolite; U.CARR, Carratelli units.International Journal of Nephrology and Renovascular Disease 2012:5
and the aliskiren-withdrawal group at baseline (Table 1) and 
at month 2 (data not shown). Increased serum potassium 
was not observed in any patients in both the aliskiren 
group and the aliskiren-withdrawal group throughout the 
treatment period.
Effect of aliskiren on BP
Figure 2 shows the changes of SBP and DBP in the 
aliskiren group and the aliskiren-withdrawal group. 
There was no statistical difference in SBP and DBP 
between the aliskiren group and the aliskiren-withdrawal 
group at baseline (Table 1 and Figure 2) and at month 2 
(Figure 2). There was also no difference in hypotension 
episodes during HD between the aliskiren group and 
the aliskiren-withdrawal group during the study period. 
SBP and DBP (± standard deviation) decreased from 
175 ± 18/80 ± 11 mmHg at baseline to 156 ± 20/76 ± 9 mmHg 
at month 2 and 155 ± 19/76 ± 9 mmHg at month 20 in 
the aliskiren group. The SBP and DBP of patients who 
received ARBs and those who did not receive ARBs 
did not show a difference in the aliskiren group dur-
ing the study period. SBP and DBP (± standard devia-
tion) also decreased from 171 ± 13/80 ± 14 mmHg 
at baseline to 159 ± 17/79 ± 12 mmHg at month 2 
and 157 ± 26/77 ± 12 mmHg at month 20 in the aliskiren-
withdrawal group. Although a trend of lower SBP was 
detected in the aliskiren-withdrawal group between month 
4 and month 7, SBP and DBP did not show a statistical 
  difference between the aliskiren group and the aliskiren-
withdrawal group throughout the follow-up period.
Blockade of RAAS by aliskiren
Each factor of RAAS at baseline in both the aliskiren 
group and the aliskiren-withdrawal group is shown in 
Table 1. There were no statistically significant differences 
in each factor of RAAS between the aliskiren group and 
the   aliskiren-withdrawal group at baseline (Table 1 and 
Figure 3) and at month 2 (Figure 3). In the aliskiren group, 
PRA, AT I, AT II, and Ald decreased from baseline to 
month 2, and this decreased level continued at month 20 
(PRA (ng/mL/h): 2.3 ± 2.6 (baseline) – 0.5 ± 0.5 (month 
2) (P , 0.05) – 0.3 ± 0.4 (month 20) (P , 0.05), AT I (pg/
mL): 909.1 ± 902.5 (baseline) – 271.7 ± 166.0 (month 2) (P 
,0.05) – 41.5 ± 14.8 (month 20) (P , 0.05), AT II (pg/mL): 
41.5 ± 45.8 (baseline) – 10.0 ± 9.9 (month 2) (P ,0.05) – 
11.0 ± 4.9 (month 20) (P , 0.05), Ald (pg/mL): 163.5 ± 214.3 
(baseline) – 74.2 ± 33.2 (month 2) (P = 0.29) – 63.4 ± 20.0 
(month 20) (P = 0.09)) (Figure 2). On the other hand, in the 
aliskiren-withdrawal group, although PRA, AT I, AT II, and 
Ald decreased at month 2 with aliskiren treatment (PRA (ng/
mL/h): 3.3 ± 2.9 (baseline) – 0.9 ± 0.7 (month 2) (P , 0.05), 
AT I (pg/mL): 999.1 ± 844.6 (baseline) – 365.6 ± 211.6 
(month 2) (P , 0.05), AT II (pg/mL): 30.6 ± 36.7 (base-
line) – 8.4 ± 10.7 (month 2) (P , 0.05), Ald (pg/mL): 
97.2 ± 57.5 (baseline) – 79.3 ± 35.7 (month 2) (P = 0.25)), 
they increased to the level of baseline upon withdrawal 
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Figure 2 Changes in systolic blood pressure and diastolic blood pressure from baseline (week 0) to month 20 in the aliskiren group and the aliskiren-withdrawal group.International Journal of Nephrology and Renovascular Disease 2012:5
of aliskiren at month 20 (PRA (ng/mL/h): 4.1 ± 3.3 
(P = 0.37), AT I (pg/mL): 801.0 ± 1032.8 (P = 0.30), AT II 
(pg/mL): 26.1 ± 17.2 (P = 0.58), Ald (pg/mL): 108.8 ± 106.7 
(P = 0.78)) (Figure 3).
Inhibition of BNP and d-ROM by aliskiren
Although there were no statistically significant differences 
in BNP and d-ROM level between the aliskiren group and 
the aliskiren-withdrawal group at baseline and at month 2, 
BNP showed a tendency to be higher in the aliskiren-withdrawal 
group (Table 1). In the aliskiren group, although there was 
no statistical significance, BNP and d-ROM tended to 
decrease from baseline to month 2 followed by a further 
decrease at month 20 (BNP (pg/mL): 248.9 ± 197.2 (base-
line) – 232.8 ± 133.1 (P = 0.71) (month 2) – 203.7 ± 113.3 
(P = 0.53) (month 20), d-ROM (Carratelli Units [U.CARR]): 
386.6 ± 123.1 (baseline) – 356.3 ± 120.5 (P = 0.16) 
(month 2) – 305.6 ± 67.4 (P = 0.08) (month 20)) (Figure 4). 
On the other hand, in the aliskiren-withdrawal group, BNP 
initially showed a tendency to decrease from baseline to 
month 2; however, it did not decrease from month 2 to month 
20 (BNP (pg/mL): 425.3 ± 207 (baseline) – 409.5 ± 287.8 
(P = 0.82) (month 2) – 412.9 ± 287.8 (P = 0.88) (month 
20)) (Figure 4). d-ROM tended to decrease from baseline 
to month 2 followed by a further decrease at month 20 
(d-ROM (U.CARR): 402.3 ± 69.0 (baseline) – 362.3 ± 47.8 
(P = 0.09) (month 2) – 336.3 ± 58.5 (P = 0.07) (month 20)) 
(Figure 4).
Discussion
The results of this study show that aliskiren significantly 
decreased SBP and DBP as well as inhibited RAAS for the 
long term in hypertensive HD patients. The aliskiren-with-
drawal patients showed re-upregulation of RAAS although 
their SBP and DBP were controlled at levels similar to those 
of the aliskiren group by antihypertensives, except for RAAS 
blockers. These results suggest that aliskiren significantly 
inhibited RAAS and had BP-lowering effects in hypertensive 
HD patients for the long-term. In addition, although statisti-
cal significance was not reached, which was considered to be 
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due to the small number of samples, BNP (pg/mL) decreased 
from baseline (248.9 ± 197.2) to month 2 (232.8 ± 133.1) 
followed by a further decrease at month 20 (203.7 ± 113.3) 
in the aliskiren group. On the other hand, in the aliskiren-
withdrawal group, although BNP (pg/mL) decreased from 
baseline (425.3 ± 207.3) to month 2 (409.5 ± 287.8 pg/mL) 
with aliskiren treatment, it did not decrease from month 
2 to month 20 (412.9 ± 287.8 pg/mL) by withdrawal of 
aliskiren under similar levels of SBP and DBP as those of 
the aliskiren group. BNP reduction has consistently been 
associated with an improved outcome in heart failure.19–21 
For instance, an increment of 10 pg/mL in BNP was associ-
ated with a 1.2% increased risk of death.19 Although we did 
not perform echocardiography to monitor the change of 
cardiac functions by aliskiren treatment during this period, 
these results suggested that both the aliskiren group and the 
aliskiren-withdrawal group may not exhibit worse cardiac 
functions. In addition, aliskiren might have cardioprotective 
effects in hypertensive HD patients. On the other hand, the 
oxidative stress marker d-ROM (U.CARR) showed a decrease 
from baseline to month 2 followed by a further decrease at 
month 20 in both the aliskiren group (386.6 ± 123.1 (base-
line) – 356.3 ± 120.5 (month 2) – 305.6 ± 67.4 (month 20)) 
and the aliskiren-withdrawal group (402.3 ± 69.0 (baseline) 
– 362.3 ± 47.8 (month 2) – 336.3 ± 58.5 (month 20)). These 
results suggest that d-ROM may be decreased in association 
with BP lowering in hypertensive HD patients. Side effects 
of aliskiren including hyperpotassemia were not detected 
in any patients throughout the follow-up period in both the 
aliskiren group and the aliskiren-withdrawal group.
We previously reported that aliskiren was effective for BP 
control and inhibition of RAAS in hypertensive HD patients 
in the short-term, namely, by 8 weeks of analysis.14 Since the 
rate of discontinuation of aliskiren treatment (150 mg/day) 
owing to symptomatic hypotension was high (eleven of 
25 patients) in this study, it may be better to reduce the 
initial dose of aliskiren to less than 150 mg/day, and careful 
  observation for BP change is required for aliskiren treatment 
in hypertensive HD patients. Further studies including kinetic 
analysis of aliskiren will need to investigate the optimal dose 
of aliskiren in hypertensive HD patients. Taken together, 
the results of this study suggest that aliskiren is effective 
for BP control and inhibition of RAAS, which may lead to 
cardiovascular protective effects in hypertensive HD patients 
in the long term, although they need careful monitoring of 
BP change.
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